Venbio Select Advisor Llc decreased its stake in Acadia Pharmaceuticals Inc (Call) (ACAD) by 74.76% based on its latest 2016Q4 regulatory filing with the SEC. Ameriprise Financial Inc. now owns 882,722 shares of the biopharmaceutical …
Baity now owns $2,134,680 of the stock according to the SEC filing. Glenn Baity, EVP AND GC reported the sale of 1,903 shares of (ACAD). The shares were purchased at an average price of $30.00. The EVP AND GC now owns $2,434,680 …
The stock has an average rating of "Buy" and a consensus target price of $42.14. Longwood Capital Partners Llc acquired 260,000 shares as Acadia Pharmaceuticals Inc (ACAD)'s stock declined 29.10%. The firm's 50-day moving average …
(NASDAQ:ACAD) has "Neutral" rating given on Friday, August 7 by Piper Jaffray. On Tuesday, November 8 the stock rating was upgraded by Bank of America to "Buy". Finally, HC Wainwright reaffirmed a "buy" rating on shares of …
Among 9 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 6 have …
If you want a Stock Review on ACAD, ADRO, AGIO, or AVXS then come over to http://dailystocktracker.com/register/ …
They now have a Dollars 60 price target on the stock. ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, …